Nidufexor is primarily investigated for its potential therapeutic applications in treating metabolic and liver-related disorders. It acts as a selective agonist for the farnesoid X receptor (FXR), a nuclear receptor involved in regulating bile acid, lipid, and glucose metabolism. This makes it a promising candidate for managing non-alcoholic steatohepatitis (NASH), a condition characterized by liver inflammation and fat accumulation. By modulating FXR activity, it helps reduce liver fat, inflammation, and fibrosis, improving overall liver function. Additionally, it is being explored for its role in improving insulin sensitivity and lipid profiles, which could benefit patients with type 2 diabetes and dyslipidemia. Its ability to regulate metabolic pathways also suggests potential applications in addressing obesity-related complications. Ongoing clinical trials aim to further validate its efficacy and safety in these therapeutic areas.